This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Trabucchi, M. Search for Related Content PubMed PubMed Citation Articles by Trabucchi, M. Social Bookmarking                   What's this?

An Economic Perspective on Alzheimer's Disease

The rapid growth of the world's Alzheimer's disease (AD) population has resulted in a tremendous financial burden on society, a situation exacerbated by the fact that the funding of health and social services faces increasing restric tions in the coming years. As a consequence, several cost-of-illness studies, aimed at assessing the total costs associated with the care of an AD patient or with individual components thereof, have been conducted, with a view to identifying areas in which costs might be reduced. For example, the Costs of Dementia (CoDem) study, described here, aims to give a profile of the total economic costs ofAD in Italy. While this study found the number of Instrumental Activities of Daily Living lost to be the principal predictor of the weekly costs for home care, other studies have reported a correlation between total cost and Mini-Mental State Examination (MMSE) score. The basis for a cor relation between cost and disease severity is discussed. Pharmacoeconomics aims to assess the cost effectiveness of interventions that may form part of an overall management strategy in AD. As institutionalization is the largest cost element in the care of any AD patient, efforts at cost containment have focused on maintaining patients at home for as long as possible. The results of studies on a number of interventions, namely, screening, reality orien tation therapy, special care units, family interventions, and drug treatment, are discussed, although the costs and, indeed, the long-term benefits associated with many of these remain unknown. Although information concerning costs is essential in health resource allocation, it is also vital that meaningful ways in which to assess quality-of- life issues be developed as the basis for genuine cost-benefit judgments. (J Geriatr Psychiatry Neurol 1999; 12:29-38).

Journal of Geriatric Psychiatry and Neurology, Vol. 12, No. 1, 29-38 (1999)
DOI: 10.1177/089198879901200107


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. H.P. Eggermont and E. J.A. Scherder Physical activity and behaviour in dementia: A review of the literature and implications for psychosocial intervention in primary care Dementia, August 1, 2006; 5(3): 411 - 428. [Abstract] [PDF]

				B. S. Bloom, S. Chhatre, and R. Jayadevappa Cost effects of a specialized care center for people with Alzheimer's disease American Journal of Alzheimer's Disease and Other Dementias, July 1, 2004; 19(4): 226 - 232. [Abstract] [PDF]

				A. Bianchetti, F. Castelletti, and M. Trabucchi Costs of dementia The British Journal of Psychiatry, December 1, 2002; 181(6): 533 - 534. [Full Text]

				M. C. Reid, P. K. Maciejewski, K. A. Hawkins, and S. T. Bogardus Jr Relationship between Alcohol Consumption and Folstein Mini-Mental Status Examination Scores among Older Cognitively Impaired Adults J Geriatr Psychiatry Neurol, April 1, 2002; 15(1): 31 - 37. [Abstract] [PDF]

				P. Werner, M. Schnaider-Beeri, J. Aharon, and M. Davidson Family Caregivers' Willingness to Pay for Drugs Indicated for the Treatment of Alzheimer's Disease: An economic or psychological model? Dementia, February 1, 2002; 1(1): 59 - 74. [Abstract] [PDF]